Image Gallery
Contact Us
For inquiries about incubator space:
Douglas Crawford, PhD
Associate Director
(415) 514-4408
douglas.crawford@qb3.org
QB3 East Bay Innovation Center
The facility
Doug Crawford and Chris Barlow explain how a Twinkie bakery in Berkeley became the next incubator in the QB3 network. More videos on the QB3 YouTube channel.
The QB3-EBIC “Bakery” incubator provides 9,300 square feet of top-quality wet-laboratories, support functions, private offices, lunch/break area, and conference rooms specifically designed to meet the needs of start-up technology companies. The facility contains a number of major items of research equipment that are available for use by tenants, including fume hoods, bio-safety cabinets, incubators, freezers, ultra low temperature freezers, an ice machine, and an autoclave. The central location in the East Bay technology corridor, less than 15 minutes away from the UC Berkeley and LBNL campuses, provides access to the world class scientific communities at these major research institutions and at local and international companies such as Novartis, Bayer HealthCare, Amyris, XOMA, and Dynavax.
Download the EBIC trifold brochure
QB3-EBIC tenants can make arrangements to use QB3 core facilities at UC Berkeley or UCSF. Direct inquiries about space to Douglas Crawford.
Location
2929 Seventh Street in the 13-building, 525,000-square-foot Aquatic Park Center research campus in West Berkeley.
Tenants
Accurus Biosciences
Accurus is a young biomedical contract research company based in the San Francisco Bay Area. The company has expertise in recombinant protein expression, stable cell line generation and hybridoma antibody technologies. Currently Accurus provides services in recombinant protein and antibody production, stable cell line generation, membrane receptor protein production and preparation, and hybridoma antibody scale-up, as well as other project support.
Epitex Biosystems
Green Pacific Biologicals
is a seed-stage company developing the next-generation eukaryotic algae platform for production of low-cost biofuel. GPB believes that nuclear genetic engineering of algae is the key to overcoming critical problems currently limiting the immense potential of algae-based biofuels. Our foundation for product development is a platform that brings genetic engineering, systems biology, and synthetic biology to generate algae with high levels of oils, oil secretion capabilities, and better growth characteristics.
Knowledge Synthesis
Lygos
Lypro Biosciences
Lypro Biosciences is a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and facilitates drug targeting to specific receptor(s).